Drugs Made in America Acquisition Corp. Signs LOI For $1B De-SPAC Deal With Power Analytics Global

On April 7, 2026, Drugs Made in America Acquisition Corp. (the "Company") entered into a letter of intent (the "LOI") with Power Analytics Global Corp., a Delaware corporation (the "Target") for a de-SPAC transaction resulting in Target becoming a public company. The terms of the transaction are subject to further negotiation and execution of a business combination agreement although it is anticipated that the valuation for Target will be approximately $1.0 billion, subject to adjustment based on due diligence, capital structure, net debt, working capital and market conditions. A copy of the Letter of Intent is filed as Exhibit 10.1 hereto and incorporated herein by reference.